Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy
- 19 November 2018
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (1) , 93-101
Abstract
OBJECTIVE Patients with type 1 diabetes and diabetic nephropathy are targets for intervention to reduce high risk of end-stage renal disease (ESRD) and deaths. This study compares risks of these outcomes in four international cohorts. RESEARCH DESIGN AND METHODS In the 1990s and early 2000s, Caucasian patients with type 1 diabetes with persistent macroalbuminuria in chronic kidney disease stages 1–3 were identified in the Joslin Clinic (U.S., 432), Finnish Diabetic Nephropathy Study (FinnDiane) (Finland, 486), Steno Diabetes Center Copenhagen (Denmark, 368), and INSERM (France, 232) and were followed for 3–18 years with annual creatinine measurements to ascertain ESRD and deaths unrelated to ESRD. RESULTS During 15,685 patient-years, 505 ESRD cases (rate 32/1,000 patient-years) and 228 deaths unrelated to ESRD (rate 14/1,000 patient-years) occurred. Risk of ESRD was associated with male sex; younger age; lower estimated glomerular filtration rate (eGFR); higher albumin/creatinine ratio, HbA1c, and systolic blood pressure; and smoking. Risk of death unrelated to ESRD was associated with older age, smoking, and higher baseline eGFR. In adjusted analysis, ESRD risk was highest in Joslin versus reference FinnDiane (hazard ratio [HR] 1.44, P = 0.003) and lowest in Steno (HR 0.54, P < 0.001). Differences in eGFR slopes paralleled risk of ESRD. Mortality unrelated to ESRD was lowest in Joslin (HR 0.68, P = 0.003 vs. the other cohorts). Competing risk did not explain international differences in the outcomes. CONCLUSIONS Despite almost universal renoprotective treatment, progression to ESRD and mortality in patients with type 1 diabetes with advanced nephropathy are still very high and differ among countries. Finding causes of these differences may help reduce risk of these outcomes.Keywords
Funding Information
- JDRF (17-2013-8)
- National Institutes of Health (P30 DK036836)
- National Institutes of Health (AG-024824, DK-041526)
- Folkhälsan Research Foundation
- Wilhelm and Else Stockmann Foundation
- Liv och Hälsa Society
- Helsinki University Central Hospital Research Funds
- Research Council of Finland (275614, 299200)
This publication has 28 references indexed in Scilit:
- Risk for End-Stage Renal Disease Over 25 Years in the Population-Based WESDR CohortDiabetes Care, 2014
- The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal diseaseKidney International, 2012
- Competing-Risk Analysis of ESRD and Death among Patients with Type 1 Diabetes and MacroalbuminuriaJournal of the American Society of Nephrology, 2011
- Risk for ESRD in Type 1 Diabetes Remains High Despite RenoprotectionJournal of the American Society of Nephrology, 2011
- Cumulative Risk, Age at Onset, and Sex-Specific Differences for Developing End-Stage Renal Disease in Young Patients With Type 1 DiabetesDiabetes, 2010
- Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With NephropathyDiabetes Care, 2010
- The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 DiabetesDiabetes, 2009
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group.Journal of Clinical Investigation, 1997
- Testing for differences in changes in the presence of censoring: Parametric and non‐parametric methodsStatistics in Medicine, 1994